financetom
Business
financetom
/
Business
/
Methanex Q2 adjusted EPS beats expectations, OCI acquisition closed
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Methanex Q2 adjusted EPS beats expectations, OCI acquisition closed
Jul 30, 2025 2:53 PM

Overview

* Methanex ( MEOH ) Q2 adjusted EPS beats analysts' expectations, per LSEG data

* Adjusted EBITDA for Q2 beats estimates despite lower realized prices, per LSEG data

* Co closed OCI acquisition, expanding production footprint in North America

Outlook

* Methanex ( MEOH ) expects 2025 production to be approximately 8.0 mln tonnes

* Company anticipates higher Q3 Adjusted EBITDA than Q2

* Methanex ( MEOH ) projects average realized price of $335-$345 per tonne for July-August

* Company sees increased sales offset by lower realized price in Q3

Result Drivers

* OCI ACQUISITION - Methanex ( MEOH ) expanded production footprint with acquisition of OCI's methanol business, enhancing access to stable natural gas supplies

* PRODUCTION VARIABILITY - Higher production in Geismar and Trinidad offset by declines in Chile, New Zealand, and Egypt due to maintenance and gas supply issues

* PRICE DECLINE - Average realized price per tonne fell, affecting net income despite operational improvements

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $0.97 $0.33 (6

Adjusted Analysts

EPS )

Q2 EPS $0.93

Q2 Beat $66 mln $21.30

Adjusted mln (3

Net Analysts

Income )

Q2 Net $64 mln

Income

Q2 Beat $183 mln $167 mln

Adjusted (5

EBITDA Analysts

)

Q2 Basic $0.95

EPS

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the commodity chemicals peer group is "buy"

* The stock recently traded at 10 times the next 12-month earnings vs. a P/E of 8 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Caterpillar, Hunt Energy Collaborate to Provide Power Services for Data Centers
Caterpillar, Hunt Energy Collaborate to Provide Power Services for Data Centers
Aug 21, 2025
09:27 AM EDT, 08/21/2025 (MT Newswires) -- Caterpillar ( CAT ) and Hunt Energy said Thursday that they have formed a collaboration to provide power services for data centers. Financial details of the collaboration were not disclosed. Caterpillar ( CAT ) will use its portfolio of power services and will provide monitoring and servicing products, the companies said. Hunt will...
ADB to provide $410 million package for Barrick-run Pakistan mine, sources say
ADB to provide $410 million package for Barrick-run Pakistan mine, sources say
Aug 21, 2025
* ADB to provide $410 million package for copper-gold mine * Package includes a $300 million in loans to Barrick Gold ( B ) (Updates throughout) By Saeed Shah and Ariba Shahid ISLAMABAD, Aug 21 (Reuters) - The Asian Development Bank will provide a $410 million financing package to help develop Pakistan's Reko Diq copper mine, one of the world's...
Crinetics Pharmaceuticals Gets FDA Orphan Drug Designation for Atumelnant
Crinetics Pharmaceuticals Gets FDA Orphan Drug Designation for Atumelnant
Aug 21, 2025
09:25 AM EDT, 08/21/2025 (MT Newswires) -- Crinetics Pharmaceuticals ( CRNX ) said Thursday the US Food and Drug Administration has granted orphan drug designation to atumelnant, its oral drug candidate for classic congenital adrenal hyperplasia. The company said the designation follows phase 2 trial results that indicated reductions in key biomarkers and clinical symptoms in adults with the condition....
AbbVie Says 2nd Phase 3 Trial Evaluating Upadacitinib for Alopecia Areata Met Primary Endpoint
AbbVie Says 2nd Phase 3 Trial Evaluating Upadacitinib for Alopecia Areata Met Primary Endpoint
Aug 21, 2025
09:29 AM EDT, 08/21/2025 (MT Newswires) -- AbbVie ( ABBV ) said Thursday that topline results from the second of two pivotal studies of a phase 3 trial showed that upadacitinib improved scalp and non-scalp hair regrowth in adult and adolescent patients with severe alopecia areata. The study achieved the primary endpoint with 45.2% and 55% of patients treated with...
Copyright 2023-2026 - www.financetom.com All Rights Reserved